Treatment Failure Due to Emergence of Resistance to Carbapenem during Therapy for *Shewanella algae* Bacteremia

Dong-Min Kim,¹,† Cheol-In Kang,¹ Chang Seop Lee,¹ Hong-Bin Kim,¹ Eui-Chong Kim,²,³ Nam Joong Kim,¹,³ Myoung-don Oh,¹,³* and Kang-Won Choe¹,³

Departments of Internal Medicine¹ and Laboratory Medicine², Seoul National University College of Medicine, and Clinical Research Institute, Seoul National University Hospital,³ Seoul, Republic of Korea.

We describe a case of bacteremia due to imipenem-susceptible *Shewanella algae*. Despite treatment with imipenem, the patient developed a spinal epidural abscess, from which imipenem-resistant *S. algae* was isolated. The development of resistance should be monitored when *S. algae* infection is treated with imipenem, even though the strain is initially susceptible to imipenem.

CASE REPORT

A 65-year-old man underwent distal pancreatectomy with cholecystectomy because of intraductal papillary mucinous tumor. On hospital day 12 (postoperative day 7), the patient complained of chills and fever. Abdominal sonography showed fluid collection in the abdomen, and percutaneous drainage was performed. Cultures of blood and percutaneous drainage fluid yielded *Shewanella algae*, which was susceptible to ceftazidime, cefepime, aztreonam, imipenem, and amikacin. It was resistant to piperacillin and gentamicin, as determined by disk diffusion testing. Based on this result, treatment with imipenem (500 mg intravenously [i.v.] every 6 h [q6h]) was instituted. Despite the treatment, the patient remained febrile. On hospital day 25, the patient became agitated and disoriented, and signs of meningismus were evident on his examination. His cerebrospinal fluid (CSF) contained 180 white blood cells/mm³. The CSF protein concentration was 307 mg/dl (reference range, 40 to 80 mg/dl). The CSF culture was negative. Imipenem treatment was changed to meropenem treatment. On hospital day 32, he complained of pain in his neck, and weakness of his left arm and left leg developed suddenly. Magnetic resonance imaging (MRI) revealed a spinal epidural abscess extending from the fourth to the sixth cervical vertebrae. The patient underwent hemilaminectomy and discectomy of C4 and C5 with drainage of the epidural abscess, which yielded *Shewanella algae* on culture. The isolate had a susceptibility profile the same as that of the previous isolate, except that it was now resistant to imipenem. The initial blood isolate of *S. algae* was susceptible to imipenem, as determined by the broth dilution test (MIC, 2 µg/ml). The *S. algae* strain isolated from the epidural abscess, however, was resistant to imipenem (imipenem MIC, 16 µg/ml; meropenem MIC, 0.5 µg/ml). Following laminectomy, the patient responded to treatment, with resolution of his fever. Based upon the susceptibility test results, cefepime (2 g i.v. q12h) was substituted for meropenem (1,000 mg i.v. q8h). On postoperative day 54, the follow-up MRI showed no definitive evidence of the epidural abscess. The patient was discharged without neurological sequelae.

*Shewanella algae* is a gram-negative bacillus that is widely distributed in the environment, and its natural habitats are water and soil. The organism was formerly called *Pseudomonas putrefaciens*, *Alteromonas putrefaciens*, *Achromobacter putrefaciens*, and CDC group Ib; and it has now been placed in the genus *Shewanella* (10). *S. algae* and *Shewanella putrefaciens* have been associated with a broad range of human infections, including skin and soft tissue infections, biliary tract infections, ocular infections, otitis media, empyema, peritonitis, and sepsis (1, 3, 4, 8, 14). Khashe and Janda have reported that *S. algae* may be the predominant human pathogen within the genus (9). *Shewanellae* are generally susceptible to most antimicrobial agents in vitro (6). However, there is little clinical experience with the treatment of *Shewanella* infections. We have described here a case of bacteremia caused by an *S. algae* isolate that was initially susceptible to imipenem, but the bacterium later became resistant to imipenem during treatment with that drug. In addition, we investigated the propensity of *S. algae* to develop resistance to imipenem by using a serial passage technique.

The two clinical isolates of imipenem-susceptible and imipenem-resistant *S. algae* were identified with a VITEK II automated system (bioMérieux, Marcy l’Etoile, France) and standard microbiological techniques (15). We performed a nucleic acid-based confirmatory test by using 16S rRNA gene sequencing analysis, as described previously, using primers fD2 (5’-ACG GCT ACC TTG TTA CGA CTT-3’) and rP2 (5’-AGT TTTGATCATGGCTGCTAG-3’) (5, 19). We compared the sequence to those available in the GenBank and EMBL databases by using the Clustal N program with the BLAST package (http://www.ncbi.nlm.nih.gov/BLAST/BLAST.cgi). Over 701 bp, the isolate gene sequence shared 99%, 94%, and 94% similarity with...
similarities with the sequences of *Shewanella algae* strain ATCC 51192 (GenBank accession number AB205581), *Aeromonas veronii* strain LMG13695 (GenBank accession number AF418209), and *Shewanella putrefaciens* strain KN90 (GenBank accession number AY136079), respectively. The two clinical isolates were ultimately identified by 16S rRNA gene sequencing analysis as *S. algae*.

We also performed pulsed-field gel electrophoresis (PFGE) to confirm that the two *Shewanella* species isolated from the patient were the same strain of the bacterium. The two *S. algae* isolates were subjected to DNA restriction analysis with 10 U/μl of the SmaI enzyme in appropriate buffer. The DNA fragments were separated by pulsed-field gel electrophoresis through a 1.2% agarose gel as described previously (11). We could document the identical DNA banding patterns based on the typing results (Fig. 1).

The bacterial strain used for the in vitro test for resistance induction was the imipenem-sensitive *S. algae* strain. *Pseudomonas aeruginosa* ATCC 27853 was used as a quality control strain. Single-step resistant variants were obtained from the imipenem-sensitive *S. algae* strain on Mueller-Hinton agar containing increasing amounts of imipenem (the MIC and two, four, and eight times the MIC). MIC interpretive standards for *S. algae* have not been established. For the purposes of this study, the MIC was interpreted as susceptible or resistant according to the guidelines of the Clinical and Laboratory Standards Institute MIC interpretive standards for *P. aeruginosa*, where applicable (12, 13). The frequency of single-step resistant variants was expressed as the ratio of the number of CFU grown in the presence of the antibiotic (at twice the MIC) to the number of CFU of the control grown without imipenem, as described previously (2). Along with these assays, the imipenem-sensitive *S. algae* strain was also subjected to a serial passage experiment with imipenem, as described by Tenney et al. (18). In brief, overnight growth of the *S. algae* strain on Mueller-Hinton agar was swabbed onto Mueller-Hinton agar plates containing one-half the MIC of imipenem. At 24 h, the surface growth was picked and placed onto agar containing twice the prior concentration of imipenem. This process was repeated serially.

Single-step resistant variants were selected from the imipenem-sensitive *S. algae* strain at up to four times the MIC, whereas the resistant variant from *P. aeruginosa* ATCC 27853 could be selected at up to two times the MIC. All the resistant variants of *S. algae* selected either by single-step or by sequential stepwise passage exhibited MICs of up to 8 to 16 μg/ml, whereas those of *P. aeruginosa* ATCC 27853 showed MICs of up to 16 μg/ml. The frequencies of resistant variants from the imipenem-sensitive *S. algae* strain at twice the MIC of imipenem ranged from $0.6 \times 10^{-6}$ to $4 \times 10^{-5}$, whereas those from *P. aeruginosa* ATCC 27853 at the same MIC ranged from $0.2 \times 10^{-6}$ to $4 \times 10^{-5}$.

It is well known that the rapid emergence of imipenem resistance during treatment of patients with pseudomonal infections is relatively common, and this may lead to treatment failure when this drug has been used alone and where dense inocula are present (16, 17). Until now, however, there have been no previous reports of the emergence of resistance during treatment of an *S. algae* infection. In the present study, we documented that imipenem-susceptible *S. algae* subsequently became resistant to imipenem during treatment. We also demonstrated in vitro that *S. algae* organisms have a propensity toward resistance to imipenem. The mechanism of resistance to imipenem in the organism may be related to a carbapenem-hydrolyzing Ambler class D β-lactamase, as described previously (7). PCR experiments were performed as described previously with the specific primers OXA-55/1 (5′-CATCTACCTTTAAAATTCCC-3′) and OXA-55/2 (5′-AGCTGTTCCTGCAGCTGTTCCTGC-3′) to amplify the bla_{OXA-55} gene from the imipenem-resistant *S. algae* isolate. We could detect a chromosome-encoded carbapenem-hydrolyzing Ambler class D β-lactamase from our *S. algae* isolates. This suggests that a carbapenem-hydrolyzing β-lactamase plays a central role in the emergence of resistance to imipenem in *S. algae* (7). When it is considered that the two isolates had the same PFGE pulstype and that we had detected Ambler class D β-lactamase by performing PCR, it is likely that the emergence of resistance was due to a mutation that resulted in the derepression of Ambler class D β-lactamase synthesis. It would be of interest to know why the difference in antibiotic susceptibility between cefepime and carbapenem occurred. It might have been due to the difference in the rates of hydrolysis between cefepime and carbapenem. Further studies are required, however, to test the relevance of these possibilities.

This case is clinically significant in two aspects. First, this is the first case report of the emergence of resistance to imipenem in a patient with *S. algae* bacteremia treated with imipenem. Second, to our knowledge, this is the first report of a spinal epidural abscess caused by *S. algae*. Our case highlights the fact that clinicians should be aware of the potential for clinical failure when imipenem is used for the treatment of serious infections caused by *S. algae*.

We are grateful to Yeong Seon Lee and Jeong Ok Cha from the Department of Bacteriology, National Institute of Health, Korea Cen-
REFERENCES


